Skip to Content

Inflammatory joint disease: Adalimumab serum levels, anti-drug antibodies and drug survival

In this MEDtalk, Ingrid Jyssum presents a research project related to the use of therapeutic drug monitoring in the treatment of inflammatory joint diseases. The study focuses on the drug adalimumab and its serum levels and drug survival as well as the impact of anti-drug antibodies on treatment outcomes.

Ingrid Jyssum

Få tilgang

Hvis du er lege, sykepleier eller annen helsepersonell, kan du få tilgang til hele artikkelen ved å opprette en profil på BestPractice Nordic.

Back to top